

## CORPORATE HEADQUARTERS

1505 Adams Drive, Suite D  
Menlo Park, CA  
Phone: 650.889.5020  
[www.biopharmx.com](http://www.biopharmx.com)  
[investors@biopharmx.com](mailto:investors@biopharmx.com)

**Industry:** Pharmaceutical Drug Development, Biological Sciences

**NYSE MKT Listing:** BPMX

**Fiscal Year End:** January 31

## MANAGEMENT TEAM

### Anja Krammer

*President & co-founder*

### Greg Kitchener

*Chief Financial Officer*

### Kin Chan, PhD

*Executive Vice President of Technology*

### AnnaMarie Daniels

*Executive Vice President of Regulatory & Clinical Affairs*

### Marie-Louise Bots

*Senior Vice President of Business Development*

## ABOUT BIOPHARMX NYSE MKT: BPMX

BioPharmX<sup>®</sup> Corporation is a specialty pharmaceutical company focused on utilizing proprietary drug delivery technologies to develop and commercialize novel prescription products for the largely underserved dermatology market. The company's focus is to develop products that treat health or age-related conditions that: (1) are not presently being addressed or treated or (2) are currently treated with suboptimal drug therapies or drug delivery approaches.

BioPharmX Corporation's strategy is to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for FDA-approved active pharmaceutical ingredients (APIs) and biological materials, while in appropriate circumstances, reducing the time, cost, and risk typically associated with new product development by repurposing drugs with demonstrated safety profiles and taking advantage of the regulatory pathway under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This approach may reduce drug development risk and could reduce the time and resources required for development.

BioPharmX deploys a market-driven approach to identifying the limitations of current treatment options and solving those limitations by improving the efficacy, safety, and/or patient experience. This approach has resulted in the following drug delivery systems:


**Topical Delivery System**  
Anhydrous hydrophilic topical delivery system

**Injectable System**  
Biologics targeting the aesthetic market

**Encapsulation System**  
Deliver hydrophilic, water-sensitive agents

**Iodine System**  
Solid dose oral molecular iodine

## TARGET MARKETS



### Dermatology

Therapeutics  
Aesthetics  
Cosmetics

### Women's Health

Breast Health  
Gynecology

## PRESCRIPTION PRODUCTS IN DEVELOPMENT

**BPX-01** – BPX-01 combines minocycline, the most widely-used oral antibiotic drug for the treatment of moderate-to-severe acne with a proprietary anhydrous hydrophilic topical delivery system specifically designed to localize the delivery of the drug while minimizing systemic side effects. This proprietary topical delivery system allows us to minimize the dosage required by improving bioavailability with enhanced and targeted delivery of a fully solubilized API. BPX-01 is currently the subject of a phase 2b dose-finding study with results expected in 1H 2017.

**BPX-02** – BPX-02 is an injectable, biologics-based product for aesthetic dermatology. This research-stage product candidate stems from our injectable system and is expected to enter preclinical testing in calendar year 2017.

**BPX-03** – BPX-03, the first prescription product candidate stemming from our iodine system, is a molecular iodine (I<sub>2</sub>) pill for the treatment of moderate-to-severe, periodic breast pain associated with fibrocystic breast condition and cyclic mastalgia. BPX-03 is poised to begin Phase 3.


## DELIVERY PATHWAYS

BioPharmX creates unique drug delivery systems and ultimately prescription products for IP licensing or direct commercialization. As we develop the most efficient delivery method for underserved indications within the dermatology market, we do not invest in manufacturing infrastructure nor restrict ourselves with core focus on therapeutics or aesthetics. We believe our drug delivery platforms have applications in both the therapeutic and aesthetic dermatology markets and therefore expect our source of future revenues to come from both reimbursed therapies and cash-based procedures.


### Proprietary Formulations and Protocols



### Delivery Methods



### Payment Methods



BioPharmX continues to focus on key product milestones including: (1) conducting Phase 2 clinical trials for a topical antibiotic to treat acne, (2) advancing preclinical development of an injectable biologics for dermatology, (3) exploring commercial growth opportunities for Violet iodine, a patented molecular iodine supplement for alleviating the symptoms of FBC, through strategic partnerships with women's health and/or consumer health companies, and (4) advancing additional products in its R&D pipeline.

### FORWARD-LOOKING STATEMENTS

Statements in this Fact Sheet relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements." These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company's filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risk that the company may not successfully implement its business plans and strategy. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.